Compare Snowflake Inc (SNOW) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Snowflake Inc vs Viatris Inc — how do they compare? Snowflake Inc trades at $368.99 (market cap $121.15B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: Snowflake Inc is far larger — about 6× Viatris Inc's market cap, and Viatris Inc pays a 2.75% dividend while Snowflake Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Snowflake Inc for 54 Days and Viatris Inc for 57 Days on average.
| SNOW | VTRS | |
|---|---|---|
Market Cap | $121.15B | $20.03B |
Volume | 3,986,549 | 14,109,977 |
Sector | Technology | Health |
52-Week High | $356.47 | $18.27 |
52-Week Low | $121.11 | $9.74 |
Typical Hold Time | 54 Days | 57 Days |
Enterprise Value | $121.57B | $32.15B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNOW trades at $368.89, up 10.83% in 24 hours, reflecting strong momentum. The technical outlook is bullish, with the stock above key support levels. Fundamentally, revenue growth is robust, reaching $3.63B in 2025, but profitability remains a challenge with a net income margin of -20.07%. Recent news highlights strategic partnerships, such as the UiPath integration, and a $3.75B convertible note offering to fund growth initiatives.
The outlook is supported by analyst optimism, with an 81% buy rating and a $418.03 price target, suggesting 13% upside. However, persistent losses, high valuation multiples, and execution risks in a competitive cloud data market pose significant challenges. Investor sentiment is positive but cautious due to these fundamental headwinds.
Viatris (VTRS) trades at $17.64, up 0.86% on the day, with a bullish technical signal from moving averages and oversold RSI levels. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $0.69 exceeding expectations. Revenue for 2025 was $14.3 billion, though net income was negative. Analyst consensus is a 'Buy' with a $22.17 price target, representing 26% upside. Recent news highlights include a new drug approval in Japan and recognition as a top employer.
The outlook for VTRS is cautiously optimistic, supported by earnings beats and a positive analyst stance, but tempered by negative profit margins and high debt. Key opportunities include operational cash flow strength and pipeline progress, while risks involve sustained profitability challenges and competitive pressures in the generics market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Snowflake Inc
Founded in 2012, Snowflake is a data lake, warehousing, and sharing company that came public in 2020. To date, the company has over 3,000 customers including nearly 30% of the Fortune 500 as its customers. Snowflake's data lake stores unstructured and semistructured data that can then be used in analytics to create insights stored in its data warehouse. Snowflake's data sharing capability allows enterprises to easily buy and ingest data almost instantaneously compared with a traditionally months-long process. Overall, the company is known for the fact that all of its data solutions that can be hosted on various public clouds.
Read more on SNOW →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
